Related Experiment Video
Updated: Sep 10, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Metabolism and Psychosexual Health in Patients With Polycystic Ovary Syndrome: A Cross-Sectional Study
Konstantin Hofmann1, Susanne Singer2, Susanne Theis1
1Department of Obstetrics and Gynecology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, DEU.
Abstract:
Psychosexual impairments in women with polycystic ovary syndrome (PCOS), often linked to depression, low self-esteem, and negative body image, significantly reduce quality of life. Although metabolic dysfunctions such as insulin resistance and obesity are key features of PCOS, their impact on psychosexual health remains poorly understood. This cross-sectional study aimed to examine the association between metabolic markers and psychosexual functioning in PCOS patients. Participants were recruited from the University Medical Center Mainz and diagnosed using the Rotterdam criteria. Assessments included hormonal and metabolic parameters - such as insulin resistance, body mass index (BMI), fatty liver index (FLI), and visceral adiposity index (VAI) - as well as psychosexual health, using the Female Sexual Function Index (FSFI) and the Hospital Anxiety and Depression Scale (HADS). Logistic regression analyses revealed that visceral adiposity was associated with reduced sexual desire (odds ratio (OR) 2.56, p=0.016), and higher BMI (≥25 kg/m²) with reduced sexual satisfaction (OR 3.56, p=0.049). Elevated insulin resistance (homeostatic model assessment for insulin resistance (HOMA-IR) >5) and FLI (≥60) were associated with increased anxiety and depression, respectively. Overall, higher metabolic burden correlated with impaired sexual function and mental health. These findings highlight the importance of integrating metabolic and psychosexual assessments in PCOS care to better address patients' comprehensive well-being.
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Oogenesis
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Drug Metabolism: Phase I Reactions
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Regulation of Metabolism

